Coexpression of her2 and p53 in gastric and esophageal adenocarcinoma

الملخص EN

Background and objectives: Gastric and esophageal adenocarcinoma remains deadly diseases with an on rise incidence.

The recently discovered cancer-related molecular markers, such as HER2 and p53, help facilitate response to preoperative therapy and improve overall survival.

This study was aimed to detect the immunoexpression of HER2 and p53 in gastric and esophageal adenocarcinoma and to determine the association of these two markers with clinicopathological parameters.

Method: The study was conducted in the Central Laboratory and Directorate of Health, Duhok-Iraq during a period from May 2009 to September 2014 on 101 gastric and esophageal adenocarcinoma cases.

Using monoclonal antibodies against HER2 receptors and p53 nuclear protein, slides were stained with the fully automated immunostaining instrument, Ventana Benchmark.

Results: Total positive HER2 immunoexpression was demonstrated in 33.7% of cases with a significantly higher dense HER2 (3+) expression in esophageal adenocarcinoma compared with its gastric counterpart.

p53 nuclear staining was observed in 62.4% of cases; it was significantly higher in gastric cancer than esophageal adenocarcinoma.

HER2 was limited to the intestinal type whereas p53 was found to be expressed in both intestinal and diffuse types.

No significant coexpression was demonstrated between HER2 and p53 in any of gastric or esophageal adenocarcinoma.

Conclusions: HER2 expression was limited to the intestinal type gastric adenocarcinoma.

No significant coexpression of HER2 and p53 was demonstrated in both of gastric and esophageal adenocarcinoma.